Alpine Woods Capital Investors’s Ionis Pharmaceuticals IONS Stock Holding History

Alpine Woods Capital Investors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,300	Closed	-$318K	–	268
2019 Q3	$318K	Hold	5,300	–	–	0.06%	208
2019 Q2	$341K	Buy	+5,300	New	+$375K	0.07%	214
2017 Q3	–	Sell	-10,000	Closed	-$509K	–	458
2017 Q2	$509K	Hold	10,000	–	–	0.03%	301
2017 Q1	$402K	Hold	10,000	–	–	0.02%	336
2016 Q4	$478K	Hold	10,000	–	–	0.03%	313
2016 Q3	$366K	Hold	10,000	–	–	0.02%	344
2016 Q2	$233K	Hold	10,000	–	–	0.01%	373
2016 Q1	$405K	Hold	10,000	–	–	0.02%	319
2015 Q4	$619K	Hold	10,000	–	–	0.03%	305
2015 Q3	$404K	Hold	10,000	–	–	0.02%	349
2015 Q2	$576K	Hold	10,000	–	–	0.03%	299
2015 Q1	$637K	Hold	10,000	–	–	0.03%	298
2014 Q4	$617K	Sell	10,000 -10,000	-50%	-$493K	0.03%	301
2014 Q3	$777K	Sell	20,000 -10	-0%	-$354	0.04%	272
2014 Q2	$689	Buy	+20,010	New	+$630K	0.02%	276

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Alpine Woods Capital Investors's IONS Position: Q4 2019 in Review

Alpine Woods Capital Investors sold out of Ionis Pharmaceuticals (IONS) in Q4 2019, closing a stake of 5,300 shares — an estimated $318K sold.

Alpine Woods Capital Investors first reported a position in IONS in Q2 2014 and held it in 15 quarters. The position peaked at $777K in Q3 2014. 391 funds tracked by Wall St. Rank hold IONS as of Q4 2019.

Alpine Woods Capital Investors reported no remaining Ionis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Alpine Woods Capital Investors sold 5,300 Ionis Pharmaceuticals shares in Q4 2019, an estimated $318K.
Alpine Woods Capital Investors first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 15 quarters.
Alpine Woods Capital Investors's Ionis Pharmaceuticals position peaked at $777K in Q3 2014.
391 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2019.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2019, filed 7 Feb 2020.